About C R Bard (NYSE:BCR)

C. R. Bard, Inc. (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis. Its vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease and end-stage renal disease. Its urology products include basic urology drainage products, fecal and urinary continence products, urological specialty products and Targeted Temperature Management products. Its oncology products cover a range of devices used in the treatment and management of various cancers, and other diseases and disorders. Its surgical specialty products include implanted patches and fixation devices for hernia and soft tissue repairs.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryHealth Care Equipment
SectorN/A
SymbolNYSE:BCR
CUSIP06738310
Phone+1-908-2778000
Debt
Debt-to-Equity Ratio0.57%
Current Ratio1.72%
Quick Ratio1.37%
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E Ratio27.86
P/E Growth2.53
Sales & Book Value
Annual Sales$3.71 billion
Price / Sales6.50
Cash Flow$13.4760 per share
Price / Cash24.58
Book Value$22.78 per share
Price / Book14.54
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$531.40 million
Net Margins9.51%
Return on Equity19.39%
Return on Assets6.91%
Miscellaneous
Employees16,300
Outstanding Shares72,890,000
C R Bard (NYSE:BCR) Frequently Asked Questions
What is C R Bard's stock symbol?
C R Bard trades on the New York Stock Exchange (NYSE) under the ticker symbol "BCR."
How often does C R Bard pay dividends? What is the dividend yield for C R Bard?
C R Bard announced a quarterly dividend on Wednesday, October 11th. Stockholders of record on Friday, December 8th will be paid a dividend of $0.26 per share on Friday, December 29th. This represents a $1.04 annualized dividend and a dividend yield of 0.31%. The ex-dividend date of this dividend is Thursday, December 7th. View C R Bard's Dividend History.
How were C R Bard's earnings last quarter?
C R Bard Inc (NYSE:BCR) announced its quarterly earnings data on Wednesday, October, 25th. The medical instruments supplier reported $3.02 EPS for the quarter, topping analysts' consensus estimates of $2.96 by $0.06. The medical instruments supplier earned $989.80 million during the quarter, compared to analysts' expectations of $990.64 million. C R Bard had a return on equity of 19.39% and a net margin of 9.51%. The firm's revenue for the quarter was up 5.1% on a year-over-year basis. During the same period in the prior year, the firm earned $2.64 EPS. View C R Bard's Earnings History.
What price target have analysts set for BCR?
7 brokers have issued 1-year target prices for C R Bard's stock. Their forecasts range from $265.00 to $337.00. On average, they expect C R Bard's share price to reach $310.60 in the next twelve months. View Analyst Ratings for C R Bard.
What are Wall Street analysts saying about C R Bard stock?
Here are some recent quotes from research analysts about C R Bard stock:
- 1. According to Zacks Investment Research, "In the last year, C. R. Bard has outperformed the broader industry trends with respect to price performance. Looking forward C. R. Bard is expected to benefit from the impending merger with Becton, Dickinson and Company, especially in the areas of medication management and infection prevention. The $24 billion transaction is expected to close in the fourth quarter of 2017. We believe the development will provide benefits to the combined entity and bolster its foothold in the global medical devices market. The growing adoption of Lutonix DCB is also expected to drive top-line growth in the coming quarters.However, a challenging Med-tech environment is a major concern. The company witnesses significant pricing pressure as well. Additionally, cutthroat competition in the hernia fixation and peripheral stent businesses are likely to dent growth. " (12/26/2017)
- 2. Needham & Company LLC analysts commented, "BCR’s 3Q17 revenue missed and EPS beat consensus and management raised its 2017 revenue and EPS guidance. Revenue growth slowed somewhat to 5.0% in 3Q17 from 6.4% in 2Q17 as three of four segments missed consensus. Revenue growth faced a 1.5% headwind, attributable to the impact from the hurricanes and a Surgical Sealant supply issue, both equally. We have maintained our revenue and EPS estimates." (10/26/2017)
Who are some of C R Bard's key competitors?
Some companies that are related to C R Bard include Orange (ORAN), Capital One (COF), John Deere (DE), Simon Property Group (SPG), Valero Energy (VLO), Royal Bank of Scotland Group (RBS), Mizuho Financial Group (MFG), Fiat Chrysler Automobiles (FCAU), Southern (SO), Halliburton (HAL), Prudential Financial (PRU), BHP Billiton (BBL), Ecopetrol (EC), Emerson Electric (EMR), Constellation Brands (STZ), Southern Copper (SCCO), Intercontinental Exchange (ICE) and Praxair (PX).
Who are C R Bard's key executives?
C R Bard's management team includes the folowing people:
- Timothy M. Ring, Chairman of the Board, Chief Executive Officer (Age 59)
- John H. Weiland, President, Vice Chairman of the Board, Chief Operating Officer (Age 61)
- James C. Beasley, Group President (Age 53)
- Timothy P. Collins, Group President (Age 56)
- John P. Groetelaars, Group President (Age 50)
- Christopher S. Holland, Chief Financial Officer, Senior Vice President (Age 50)
- Samrat S. Khichi, Senior Vice President, General Counsel, Secretary (Age 49)
- John A. DeFord Ph.D., Senior Vice President - Science, Technology and Clinical Affairs (Age 55)
- Frank Lupisella Jr., Vice President, Controller (Age 56)
- Betty D. Larson, Vice President - Human Resources (Age 41)
Has C R Bard been receiving favorable news coverage?
News articles about BCR stock have been trending somewhat positive on Sunday, Accern Sentiment reports. The research group ranks the sentiment of press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. C R Bard earned a coverage optimism score of 0.16 on Accern's scale. They also assigned news stories about the medical instruments supplier an impact score of 47.19 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next few days.
How do I buy shares of C R Bard?
Shares of BCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is C R Bard's stock price today?
One share of BCR stock can currently be purchased for approximately $331.24.
How big of a company is C R Bard?
C R Bard has a market capitalization of $24.14 billion and generates $3.71 billion in revenue each year. C R Bard employs 16,300 workers across the globe.
How can I contact C R Bard?
C R Bard's mailing address is 730 Central Ave, NEW PROVIDENCE, NJ 07974-1139, United States. The medical instruments supplier can be reached via phone at +1-908-2778000.
MarketBeat Community Rating for C R Bard (BCR)
MarketBeat's community ratings are surveys of what our community members think about C R Bard and other stocks. Vote "Outperform" if you believe BCR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BCR will underperform the S&P 500 over the long term. You may vote once every thirty days.
C R Bard (NYSE:BCR) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
8 Wall Street analysts have issued ratings and price targets for C R Bard in the last 12 months. Their average twelve-month price target is $310.60, suggesting that the stock has a possible downside of 6.23%. The high price target for BCR is $337.00 and the low price target for BCR is $265.00. There are currently 8 hold ratings for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
Consensus Rating: | Hold | Hold | Hold | Hold |
Consensus Rating Score: | 2.00 | 2.00 | 2.00 | 2.22 |
Ratings Breakdown: | 0 Sell Rating(s) 8 Hold Rating(s) 0 Buy Rating(s) 0 Strong Buy Rating(s) | 0 Sell Rating(s) 8 Hold Rating(s) 0 Buy Rating(s) 0 Strong Buy Rating(s) | 0 Sell Rating(s) 8 Hold Rating(s) 0 Buy Rating(s) 0 Strong Buy Rating(s) | 0 Sell Rating(s) 8 Hold Rating(s) 0 Buy Rating(s) 1 Strong Buy Rating(s) |
Consensus Price Target: | $310.60 | $310.60 | $301.3333 | $282.2857 |
Price Target Upside: | 6.23% downside | 7.01% downside | 9.78% downside | 11.87% downside |
C R Bard (NYSE:BCR) Consensus Price Target History

C R Bard (NYSE:BCR) Analyst Ratings History
Show:
(Data available from 4/22/2016 forward)
C R Bard (NYSE:BCR) Dividend Information
C R Bard pays an annual dividend of $0.78 per share, with a dividend yield of 0.24%. BCR's most recent quarterly dividend payment was Friday, December 29. The company has grown its dividend for the last 46 consecutive years and is increasing its dividend by an average of 6.50% each year.
Most Recent Dividend: | 12/29/2017 |
Annual Dividend: | $0.78 |
Dividend Yield: | 0.24% |
Dividend Growth: | 6.50% (3 Year Average) |
Payout Ratio: | 6.56% (Based on This Year's Estimates) 6.01% (Based on Next Year's Estimates)
|
Track Record: | 46 Years of Consecutive Dividend Growth |
Frequency: | Quarterly Dividend |
C R Bard (NYSE:BCR) Dividend History by Quarter
Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
---|
10/11/2017 | quarterly | $0.26 | 0.32% | 12/7/2017 | 12/8/2017 | 12/29/2017 |
6/14/2017 | quarterly | $0.26 | 0.33% | 7/20/2017 | 7/24/2017 | 8/4/2017 |
4/19/2017 | quarterly | $0.26 | 0.41% | 4/27/2017 | 5/1/2017 | 5/12/2017 |
12/14/2016 | quarterly | $0.26 | 0.47% | 1/19/2017 | 1/23/2017 | 2/3/2017 |
10/12/2016 | quarterly | $0.26 | 0.48% | 10/20/2016 | 10/24/2016 | 11/4/2016 |
6/8/2016 | quarterly | $0.26 | 0.46% | 7/14/2016 | 7/18/2016 | 7/29/2016 |
4/20/2016 | quarterly | $0.24 | 0.46% | 4/28/2016 | 5/2/2016 | 5/13/2016 |
12/9/2015 | quarterly | $0.24 | 0.52% | 1/21/2016 | 1/25/2016 | 2/5/2016 |
10/14/2015 | quarterly | $0.24 | 0.5% | 10/22/2015 | 10/26/2015 | 11/6/2015 |
6/10/2015 | quarterly | $0.24 | 0.56% | 7/16/2015 | 7/20/2015 | 7/31/2015 |
4/15/2015 | quarterly | $0.22 | 0.52% | 4/23/2015 | 4/27/2015 | 5/8/2015 |
12/10/2014 | quarterly | $0.22 | 0.52% | 1/22/2015 | 1/26/2015 | 2/6/2015 |
10/8/2014 | quarterly | $0.22 | 0.59% | 10/16/2014 | 10/20/2014 | 10/31/2014 |
6/11/2014 | quarterly | $0.22 | 0.62% | 7/17/2014 | 7/21/2014 | 8/1/2014 |
4/16/2014 | quarterly | $0.21 | 0.6% | 4/24/2014 | 4/28/2014 | 5/9/2014 |
12/11/2013 | quarterly | $0.21 | 0.63% | 1/16/2014 | 1/21/2014 | 1/31/2014 |
10/9/2013 | quarterly | $0.21 | 0.72% | 10/17/2013 | 10/21/2013 | 11/1/2013 |
6/12/2013 | quarterly | $0.21 | 0.77% | 7/18/2013 | 7/22/2013 | 8/2/2013 |
4/17/2013 | quarterly | $0.20 | 0.8% | 4/25/2013 | 4/29/2013 | 5/10/2013 |
12/12/2012 | quarterly | $0.20 | 0.83% | 1/17/2013 | 1/22/2013 | 2/1/2013 |
(Data available from 1/1/2013 forward)
C R Bard (NYSE BCR) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 0.80%
Institutional Ownership Percentage: 79.11%
C R Bard (NYSE BCR) Insider Trading History
Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
---|
12/20/2017 | John A. Deford | VP | Sell | 14,107 | $333.48 | $4,704,402.36 | | |
12/14/2017 | Jim C Beasley | Insider | Sell | 3,395 | $332.00 | $1,127,140.00 | 25,630 | |
12/11/2017 | Jim C Beasley | Insider | Sell | 15,044 | $332.00 | $4,994,608.00 | | |
11/7/2017 | John H Weiland | Vice Chairman | Sell | 33,435 | $333.31 | $11,144,219.85 | 76,331 | |
11/2/2017 | Christopher S. Holland | Insider | Sell | 38,242 | $334.04 | $12,774,357.68 | | |
11/2/2017 | Frank Lupisella Jr | VP | Sell | 7,035 | $334.70 | $2,354,614.50 | 13,824 | |
10/30/2017 | David M. Barrett | Director | Sell | 3,344 | $327.31 | $1,094,524.64 | | |
10/20/2017 | Betty D Larson | VP | Sell | 5,906 | $330.16 | $1,949,924.96 | 10,753 | |
10/18/2017 | Frank Lupisella, Jr. | VP | Sell | 9,173 | $325.00 | $2,981,225.00 | | |
10/12/2017 | Timothy P Collins | Insider | Sell | 55,818 | $322.03 | $17,975,070.54 | | |
10/9/2017 | Timothy P Collins | Insider | Sell | 8,388 | $322.00 | $2,700,936.00 | | |
9/29/2017 | Sharon M. Luboff | Insider | Sell | 30,252 | $320.00 | $9,680,640.00 | | |
8/10/2017 | John P Groetelaars | Insider | Sell | 23,687 | $318.73 | $7,549,757.51 | 31,445 | |
4/24/2017 | Frank Lupisella Jr | VP | Sell | 3,622 | $304.00 | $1,101,088.00 | 10,139 | |
2/21/2017 | Jim C Beasley | Insider | Sell | 4,390 | $245.00 | $1,075,550.00 | 26,625 | |
2/14/2017 | John A Deford | VP | Sell | 2,788 | $240.51 | $670,541.88 | 24,684 | |
2/14/2017 | John H Weiland | Vice Chairman | Sell | 14,091 | $240.49 | $3,388,744.59 | 68,978 | |
2/14/2017 | John P Groetelaars | Insider | Sell | 732 | $240.49 | $176,038.68 | 19,695 | |
2/14/2017 | Timothy M Ring | Chairman | Sell | 14,425 | $240.50 | $3,469,212.50 | 100,283 | |
2/13/2017 | John A. Deford | VP | Sell | 469 | $240.07 | $112,592.83 | | |
2/13/2017 | John H Weiland | Vice Chairman | Sell | 1,274 | $240.00 | $305,760.00 | 70,033 | |
2/13/2017 | Timothy M Ring | Chairman | Sell | 1,767 | $240.02 | $424,115.34 | 103,906 | |
2/13/2017 | Timothy P Collins | Insider | Sell | 642 | $240.30 | $154,272.60 | 34,515 | |
2/10/2017 | Betty D Larson | VP | Sell | 3,292 | $240.92 | $793,108.64 | 8,399 | |
2/9/2017 | Jim C Beasley | Insider | Sell | 8,593 | $239.58 | $2,058,710.94 | 34,415 | |
2/9/2017 | John A. Deford | VP | Sell | 5,816 | $239.58 | $1,393,397.28 | | |
2/9/2017 | John H Weiland | Vice Chairman | Sell | 14,281 | $239.54 | $3,420,870.74 | 83,613 | |
2/9/2017 | Timothy M Ring | Chairman | Sell | 20,324 | $239.56 | $4,868,817.44 | 127,954 | |
1/31/2017 | Gail K Naughton | Director | Sell | 367 | $236.22 | $86,692.74 | 1,620 | |
1/11/2017 | John P Groetelaars | Insider | Sell | 573 | $235.00 | $134,655.00 | 16,554 | |
1/10/2017 | Frank Lupisella, Jr. | VP | Sell | 2,945 | $232.00 | $683,240.00 | | |
1/9/2017 | Frank Lupisella, Jr. | VP | Sell | 210 | $232.00 | $48,720.00 | | |
12/30/2016 | Frank Lupisella Jr | VP | Sell | 237 | $226.00 | $53,562.00 | 14,520 | |
12/30/2016 | Jim C Beasley | Insider | Sell | 4,709 | $225.00 | $1,059,525.00 | 27,378 | |
12/12/2016 | John A. Deford | VP | Sell | 15,883 | $218.03 | $3,462,970.49 | | |
12/12/2016 | John H Weiland | Vice Chairman | Sell | 11,190 | $219.67 | $2,458,107.30 | 72,780 | |
12/12/2016 | Sharon M. Luboff | Insider | Sell | 6,000 | $219.00 | $1,314,000.00 | | |
10/28/2016 | Christopher S. Holland | Insider | Sell | 5,724 | $211.12 | $1,208,450.88 | | |
9/28/2016 | Timothy M Ring | Chairman | Sell | 92,293 | $227.81 | $21,025,268.33 | 145,876 | |
9/26/2016 | Timothy M Ring | Chairman | Sell | 110,000 | $228.96 | $25,185,600.00 | 96,030 | |
9/19/2016 | Betty D Larson | VP | Sell | 4,032 | $225.33 | $908,530.56 | 10,298 | |
9/6/2016 | John A. Deford | VP | Sell | 7,928 | $221.06 | $1,752,563.68 | | |
5/27/2016 | Christopher S Holland | CFO | Sell | 3,970 | $219.89 | $872,963.30 | 31,306 | |
5/17/2016 | John P Groetelaars | Insider | Sell | 1,162 | $219.88 | $255,500.56 | 17,431 | |
5/12/2016 | Tommy G Thompson | Director | Sell | 500 | $219.52 | $109,760.00 | 7,036 | |
5/5/2016 | Tony L White | Director | Sell | 1,200 | $216.19 | $259,428.00 | 14,671 | |
4/28/2016 | Jim C Beasley | Insider | Sell | 4,709 | $215.00 | $1,012,435.00 | 27,378 | |
4/27/2016 | Sharon M Luboff | VP | Sell | 10,000 | $210.00 | $2,100,000.00 | 33,706 | |
3/29/2016 | Christopher S Holland | CFO | Sell | 1,650 | $200.00 | $330,000.00 | 27,335 | |
2/25/2016 | Jim C Beasley | Insider | Sell | 1,113 | $195.27 | $217,335.51 | 22,669 | |
2/23/2016 | Frank Lupisella Jr | VP | Sell | 2,300 | $190.25 | $437,575.00 | 14,495 | |
2/22/2016 | Christopher S Holland | CFO | Sell | 618 | $190.00 | $117,420.00 | 28,985 | |
2/22/2016 | Patricia G Christian | VP | Sell | 3,182 | $190.00 | $604,580.00 | 9,240 | |
2/17/2016 | John A. Deford | VP | Sell | 661 | $187.44 | $123,897.84 | 21,607 | |
2/17/2016 | John H. Weiland | COO | Sell | 1,618 | $187.45 | $303,294.10 | 61,590 | |
2/17/2016 | Timothy M. Ring | CEO | Sell | 2,453 | $187.62 | $460,231.86 | 97,370 | |
2/17/2016 | Timothy P. Collins | insider | Sell | 974 | $187.48 | $182,605.52 | 29,276 | |
2/16/2016 | Anthony Welters | Director | Sell | 1,784 | $187.47 | $334,446.48 | 1,908 | |
2/12/2016 | Christopher S. Holland | CFO | Sell | 6,297 | $181.08 | $1,140,260.76 | 29,603 | |
2/12/2016 | John A. Deford | VP | Sell | 6,400 | $182.40 | $1,167,360.00 | 22,855 | |
2/12/2016 | John H. Weiland | COO | Sell | 15,632 | $182.86 | $2,858,467.52 | 64,603 | |
2/12/2016 | Timothy M. Ring | CEO | Sell | 24,003 | $182.76 | $4,386,788.28 | 102,200 | |
2/12/2016 | Timothy P. Collins | insider | Sell | 7,893 | $182.28 | $1,438,736.04 | 31,435 | |
2/10/2016 | John P. Groetelaars | insider | Sell | 3,319 | $187.16 | $621,184.04 | 18,841 | |
2/9/2016 | John A. Deford | VP | Sell | 3,407 | $180.62 | $615,372.34 | 18,710 | |
2/9/2016 | John H. Weiland | COO | Sell | 8,898 | $181.10 | $1,611,427.80 | 53,078 | |
2/9/2016 | Timothy M. Ring | CEO | Sell | 4,836 | $181.20 | $876,283.20 | 93,896 | |
2/9/2016 | Timothy P. Collins | insider | Sell | 4,205 | $181.24 | $762,114.20 | 25,076 | |
2/2/2016 | Tommy G Thompson | Director | Sell | 2,319 | $188.75 | $437,711.25 | 6,536 | |
12/16/2015 | John H. Weiland | COO | Sell | 19,686 | $188.49 | $3,710,614.14 | 67,409 | |
12/16/2015 | Patricia G Christian | VP | Sell | 1,908 | $190.00 | $362,520.00 | 9,413 | |
12/14/2015 | Jim C. Beasley | insider | Sell | 20,577 | $184.78 | $3,802,218.06 | 24,313 | |
12/14/2015 | John A. Deford | VP | Sell | 5,627 | $184.00 | $1,035,368.00 | 23,646 | |
12/14/2015 | John H. Weiland | COO | Sell | 33,569 | $184.25 | $6,185,088.25 | 73,505 | |
11/30/2015 | Timothy M. Ring | CEO | Sell | 22,052 | $187.37 | $4,131,883.24 | 119,694 | |
10/29/2015 | Timothy M. Ring | CEO | Sell | 30,543 | $184.79 | $5,644,040.97 | 119,694 | |
10/27/2015 | Gail K. Naughton | Director | Sell | 2,458 | $181.99 | $447,331.42 | 1,556 | |
9/29/2015 | Timothy M. Ring | CEO | Sell | 40,000 | $185.16 | $7,406,400.00 | 119,694 | |
8/31/2015 | Timothy M. Ring | CEO | Sell | 40,000 | $195.17 | $7,806,800.00 | 119,694 | |
8/18/2015 | Sharon M. Luboff | VP | Sell | 2,374 | $199.76 | $474,230.24 | 28,399 | |
8/17/2015 | Sharon M Luboff | VP | Sell | 2,030 | $200.00 | $406,000.00 | | |
8/14/2015 | Tommy G Thompson | Director | Sell | 1,200 | $199.25 | $239,100.00 | | |
7/13/2015 | John P Groetelaars | Insider | Sell | 2,456 | $175.00 | $429,800.00 | | |
7/13/2015 | Timothy M Ring | CEO | Sell | 20,000 | $176.04 | $3,520,800.00 | | |
4/28/2015 | Tommy G Thompson | Director | Sell | 1,200 | $170.43 | $204,516.00 | | |
3/23/2015 | Timothy M Ring | CEO | Sell | 7,628 | $170.65 | $1,301,718.20 | | |
2/23/2015 | Timothy M Ring | CEO | Sell | 20,000 | $176.33 | $3,526,600.00 | | |
2/19/2015 | Jim C Beasley | Insider | Sell | 2,884 | $174.79 | $504,094.36 | | |
2/19/2015 | John H Weiland | COO | Sell | 8,413 | $174.99 | $1,472,190.87 | | |
2/19/2015 | John P Groetelaars | VP | Sell | 4,566 | $175.14 | $799,689.24 | | |
2/17/2015 | Jim C Beasley | Insider | Sell | 9,904 | $174.58 | $1,729,040.32 | | |
2/17/2015 | John A Deford | VP | Sell | 6,146 | $174.58 | $1,072,968.68 | | |
2/17/2015 | John H Weiland | COO | Sell | 13,616 | $174.51 | $2,376,128.16 | | |
2/17/2015 | Timothy M Ring | CEO | Sell | 6,284 | $174.75 | $1,098,129.00 | | |
2/12/2015 | Patricia G Christian | VP | Sell | 1,408 | $173.97 | $244,949.76 | | |
2/12/2015 | Timothy M Ring | CEO | Sell | 14,363 | $173.74 | $2,495,427.62 | | |
2/12/2015 | Timothy P Collins | Insider | Sell | 6,564 | $174.00 | $1,142,136.00 | | |
2/9/2015 | Anthony Welters | Director | Sell | 1,563 | $169.02 | $264,178.26 | | |
1/22/2015 | Timothy M Ring | CEO | Sell | 20,000 | $177.84 | $3,556,800.00 | | |
12/22/2014 | Timothy M Ring | CEO | Sell | 32,325 | $169.64 | $5,483,613.00 | | |
12/17/2014 | Jim C Beasley | Insider | Sell | 4,525 | $168.42 | $762,100.50 | | |
12/17/2014 | Sharon M Luboff | VP | Sell | 3,564 | $168.36 | $600,035.04 | | |
12/16/2014 | Jim C Beasley | Insider | Sell | 14,634 | $167.47 | $2,450,755.98 | | |
12/16/2014 | John A Deford | VP | Sell | 5,626 | $167.47 | $942,186.22 | | |
12/16/2014 | John H Weiland | COO | Sell | 23,093 | $166.74 | $3,850,526.82 | | |
12/16/2014 | Timothy M Ring | CEO | Sell | 15,232 | $166.60 | $2,537,651.20 | | |
12/15/2014 | John H Weiland | COO | Sell | 13,589 | $166.56 | $2,263,383.84 | | |
12/10/2014 | Patricia G Christian | VP | Sell | 1,269 | $169.20 | $214,714.80 | | |
12/9/2014 | John H Weiland | COO | Sell | 6,350 | $170.32 | $1,081,532.00 | | |
12/9/2014 | Timothy M Ring | CEO | Sell | 9,550 | $170.20 | $1,625,410.00 | | |
10/27/2014 | Sharon M Luboff | VP | Sell | 10,000 | $158.80 | $1,588,000.00 | | |
10/22/2014 | Timothy M Ring | CEO | Sell | 60,000 | $149.07 | $8,944,200.00 | | |
10/6/2014 | Timothy M Ring | CEO | Sell | 60,000 | $148.00 | $8,880,000.00 | | |
9/10/2014 | John H Weiland | COO | Sell | 27,179 | $149.50 | $4,063,260.50 | | |
9/2/2014 | Timothy M Ring | CEO | Sell | 10,228 | $148.83 | $1,522,233.24 | | |
8/4/2014 | Bronwen K Kelly | VP | Sell | 10,055 | $150.25 | $1,510,763.75 | | |
8/1/2014 | Timothy M Ring | CEO | Sell | 10,231 | $149.04 | $1,524,828.24 | | |
7/30/2014 | Timothy P Collins | Insider | Sell | 30,914 | $150.38 | $4,648,847.32 | | |
7/29/2014 | Sharon M Luboff | VP | Sell | 5,115 | $151.37 | $774,257.55 | | |
7/1/2014 | Timothy M Ring | CEO | Sell | 10,231 | $144.30 | $1,476,333.30 | | |
6/2/2014 | Timothy M Ring | CEO | Sell | 10,231 | $147.50 | $1,509,072.50 | | |
3/3/2014 | Timothy Ring | CEO | Sell | 10,231 | $142.23 | $1,455,155.13 | 172,216 | |
2/27/2014 | Sharon Luboff | VP | Sell | 9,914 | $144.86 | $1,436,142.04 | 36,958 | |
2/20/2014 | Frank Lupisella, Jr. | VP | Sell | 2,520 | $140.26 | $353,455.20 | 18,122 | |
2/18/2014 | Marc Breslawsky | Director | Sell | 2,400 | $141.34 | $339,216.00 | 12,914 | |
2/11/2014 | John Weiland | COO | Sell | 9,328 | $135.32 | $1,262,264.96 | 115,695 | |
2/11/2014 | Sharon Luboff | VP | Sell | 1,400 | $135.00 | $189,000.00 | 39,357 | |
1/16/2014 | John Weiland | COO | Sell | 81,500 | $136.13 | $11,094,595.00 | 133,483 | |
1/13/2014 | Sharon Luboff | VP | Sell | 2,500 | $135.00 | $337,500.00 | 42,381 | |
12/12/2013 | Jim Beasley | Insider | Sell | 9,802 | $133.98 | $1,313,271.96 | 39,493 | |
12/12/2013 | John Deford | VP | Sell | 2,792 | $133.98 | $374,072.16 | 33,543 | |
12/10/2013 | John Weiland | COO | Sell | 10,389 | $137.30 | $1,426,409.70 | 123,994 | |
12/10/2013 | Timothy Ring | CEO | Sell | 15,623 | $137.12 | $2,142,225.76 | 178,568 | |
12/2/2013 | Timothy Ring | CEO | Sell | 10,231 | $138.85 | $1,420,574.35 | 209,323 | |
11/6/2013 | David Barrett | Director | Sell | 1,600 | $138.13 | $221,008.00 | 2,547 | |
10/28/2013 | Herbert L Henkel | Director | Sell | 2,400 | $134.66 | $323,184.00 | | |
10/28/2013 | Sharon M Alterio | VP | Sell | 14,002 | $134.91 | $1,889,009.82 | | |
10/23/2013 | John H Weiland | COO | Sell | 60,210 | $134.01 | $8,068,742.10 | | |
10/21/2013 | John H Weiland | COO | Sell | 84,525 | $125.62 | $10,618,030.50 | | |
10/21/2013 | Timothy M Ring | CEO | Sell | 8,313 | $125.52 | $1,043,447.76 | | |
10/18/2013 | Gary D Dolch | VP | Sell | 10,000 | $125.00 | $1,250,000.00 | | |
9/24/2013 | Timothy Ring | CEO | Sell | 8,313 | $117.77 | $979,022.01 | 209,323 | |
9/9/2013 | John A Deford | VP | Sell | 28,364 | $117.89 | $3,343,831.96 | | |
9/3/2013 | Timothy Ring | CEO | Sell | 10,231 | $114.65 | $1,172,984.15 | 209,323 | |
8/30/2013 | Jim Beasley | Insider | Sell | 1,420 | $115.33 | $163,768.60 | 41,022 | |
8/21/2013 | Timothy Ring | CEO | Sell | 8,313 | $113.24 | $941,364.12 | 209,323 | |
8/12/2013 | Sharon Alterio | VP | Sell | 13,379 | $117.01 | $1,565,476.79 | 47,032 | |
8/5/2013 | Brian P Kelly | VP | Sell | 28,000 | $115.69 | $3,239,320.00 | | |
8/2/2013 | David M Barrett | Director | Sell | 1,200 | $115.70 | $138,840.00 | | |
8/2/2013 | Frank Lupisella Jr | VP | Sell | 10,500 | $115.61 | $1,213,905.00 | | |
8/1/2013 | John H Weiland | COO | Sell | 87,336 | $115.35 | $10,074,207.60 | | |
7/29/2013 | Timothy P Collins | Insider | Sell | 22,025 | $113.60 | $2,502,040.00 | | |
7/26/2013 | Anthony Welters | Director | Sell | 5,600 | $113.12 | $633,472.00 | | |
7/26/2013 | Jean F Holloway | VP | Sell | 2,275 | $113.52 | $258,258.00 | | |
7/22/2013 | Timothy M Ring | CEO | Sell | 8,312 | $113.58 | $944,076.96 | | |
6/21/2013 | Timothy M Ring | CEO | Sell | 8,312 | $110.05 | $914,735.60 | | |
6/20/2013 | Gary D Dolch | VP | Sell | 14,569 | $109.97 | $1,602,152.93 | | |
5/21/2013 | Timothy M Ring | CEO | Sell | 8,312 | $106.65 | $886,474.80 | | |
5/20/2013 | Marc C Breslawsky | Director | Sell | 2,400 | $107.20 | $257,280.00 | | |
5/8/2013 | Timothy M Ring | CEO | Sell | 8,312 | $102.00 | $847,824.00 | | |
4/11/2013 | G Mason Morfit | Insider | Sell | 300,000 | $102.47 | $30,741,000.00 | | |
4/9/2013 | Timothy M Ring | CEO | Sell | 8,312 | $102.00 | $847,824.00 | | |
(Data available from 1/1/2013 forward)
C R Bard (NYSE BCR) News Headlines
Source: |
|
Date | Headline |
---|
 | C R Bard (BCR) Receives Hold Rating from BMO Capital Markets www.americanbankingnews.com - April 19 at 5:50 PM |
 | C R Bard (BCR) Downgraded by Zacks Investment Research to Hold www.americanbankingnews.com - April 17 at 10:55 PM |
 | C R Bard (BCR) Downgraded by BidaskClub to Buy www.americanbankingnews.com - April 17 at 4:17 PM |
 | C R Bard's (BCR) Hold Rating Reiterated at Jefferies Group www.americanbankingnews.com - April 13 at 11:42 PM |
 | Hernia Mesh Lawsuit Plaintiffs Seek MDL for Product Liability Claims Involving C.R. Bard's Polypropylene Devices, Bernstein Liebhard LLP Reports www.prnewswire.com - April 13 at 3:37 PM |
 | Analyzing C R Bard (BCR) and LDR (LDRH) www.americanbankingnews.com - March 31 at 7:04 AM |
 | Head-To-Head Review: C R Bard (BCR) versus Palomar Medical Technologies (PMTI) www.americanbankingnews.com - March 29 at 3:24 AM |
 | Contrasting Given Imaging (GIVN) and C R Bard (BCR) www.americanbankingnews.com - March 18 at 5:16 AM |
 | C R Bard Inc (BCR) Given Average Rating of "Hold" by Analysts www.americanbankingnews.com - March 7 at 1:50 PM |
 | Becton Dickinson Has A Strong, Diverse Pipeline, But Is Fairly Valued, Says BMO finance.yahoo.com - March 6 at 4:54 PM |
 | Contrasting Intersect ENT (XENT) and C R Bard (BCR) www.americanbankingnews.com - February 17 at 3:06 AM |
 | C R Bard Inc (BCR) Given Consensus Recommendation of "Hold" by Brokerages www.americanbankingnews.com - February 10 at 1:38 PM |
 | C R Bard Inc (BCR) Receives Average Rating of "Hold" from Analysts www.americanbankingnews.com - January 16 at 1:40 PM |
 | KeyBanc Initiates Becton, Dickinson And Co. With Bullish Stance - Benzinga www.benzinga.com - January 5 at 1:10 PM |
 | C.R. Bard, Inc. -- Moody's withdraws C.R. Bard's ratings finance.yahoo.com - January 2 at 11:00 AM |
 | ETFs with exposure to C.R. Bard, Inc. (New Jersey) : December 29, 2017 finance.yahoo.com - December 29 at 3:45 PM |
 | BD And Bard Expect Proposed Acquisition To Close On Dec. 29 www.nasdaq.com - December 29 at 11:13 AM |
 | BD Completes Bard Acquisition, Creating New Global Health Care Leader finance.yahoo.com - December 29 at 11:13 AM |
 | BD Statement On MOFCOM Clearance Of Bard Acquisition finance.yahoo.com - December 28 at 2:21 PM |
 | NutriSystem (NTRI) Adopts Multi-Brand Strategy for 2018 finance.yahoo.com - December 28 at 2:21 PM |
 | Becton, Dickinson and Company -- Moody's downgrades Becton, Dickinson and Company to speculative grade finance.yahoo.com - December 28 at 2:21 PM |
 | Analysts Anticipate C.R. Bard, Inc. (BCR) Will Post Earnings of $3.09 Per Share www.americanbankingnews.com - December 28 at 8:18 AM |
 | Becton, Dickinson (BDX) a Step Closer to Bard Acquisition finance.yahoo.com - December 27 at 11:40 AM |
 | C.R. Bard (BCR) Stock Rating Upgraded by Zacks Investment Research www.americanbankingnews.com - December 26 at 6:28 PM |
 | C.R. Bard, Inc. (New Jersey) – Value Analysis (NYSE:BCR) : December 26, 2017 finance.yahoo.com - December 26 at 4:16 PM |
 | FTC Requires Divestiture of Two Medical Device Product Lines as Condition of Becton, Dickinson (BDX) Acquiring C. R. Bard, Inc. (BCR) www.streetinsider.com - December 23 at 3:17 AM |
 | C.R. Bard, Inc. (BCR) VP John A. Deford Sells 14,107 Shares www.americanbankingnews.com - December 22 at 5:38 PM |
 | Stock Review for Medical Supplies Investors -- CR Bard, Glaukos, Waters, and Cooper - PR Newswire (press release) www.prnewswire.com - December 22 at 5:06 PM |
 | FTC Requires Divestiture of Two Medical Device Product Lines as Condition of Becton, Dickinson (BDX) Acquiring CR ... - StreetInsider.com www.streetinsider.com - December 22 at 5:06 PM |
 | BD Statement On FTC Clearance Of Bard Acquisition finance.yahoo.com - December 22 at 5:06 PM |
 | C.R. Bard, Inc. (BCR) Given Consensus Rating of "Hold" by Analysts www.americanbankingnews.com - December 22 at 2:50 PM |
 | C.R. Bard, Inc. (New Jersey) breached its 50 day moving average in a Bearish Manner : BCR-US : December 22, 2017 finance.yahoo.com - December 22 at 11:26 AM |
 | C.R. Bard, Inc. (BCR) Insider Sells $1,127,140.00 in Stock www.americanbankingnews.com - December 18 at 8:36 PM |
 | ETFs with exposure to C.R. Bard, Inc. (New Jersey) : December 18, 2017 finance.yahoo.com - December 18 at 3:45 PM |
 | C.R. Bard, Inc. (BCR) Insider Sells $4,994,608.00 in Stock www.americanbankingnews.com - December 13 at 5:26 PM |
 | C.R. Bard, Inc. (BCR) Expected to Announce Quarterly Sales of $1.02 Billion www.americanbankingnews.com - December 13 at 12:34 PM |
 | Zacks: Brokerages Expect C.R. Bard, Inc. (BCR) to Post $3.11 Earnings Per Share www.americanbankingnews.com - December 11 at 1:24 AM |
 | C.R. Bard, Inc. (New Jersey) : BCR-US: Dividend Analysis : December 08th, 2017 (record date) : By the numbers : December 8, 2017 finance.yahoo.com - December 8 at 11:30 AM |
 | ETFs with exposure to C.R. Bard, Inc. (New Jersey) : December 7, 2017 finance.yahoo.com - December 7 at 3:53 PM |
 | C.R. Bard (BCR) Downgraded to "Hold" at ValuEngine www.americanbankingnews.com - December 3 at 10:04 PM |
 | How Does C R Bard Inc’s (BCR) EPS Growth Stack Up Against Industry Performance? finance.yahoo.com - December 3 at 3:46 PM |
 | Financial Comparison: C.R. Bard (BCR) & Sientra (SIEN) www.americanbankingnews.com - December 2 at 11:28 AM |
 | ETFs with exposure to C.R. Bard, Inc. (New Jersey) : November 27, 2017 finance.yahoo.com - November 27 at 5:12 PM |
 | C.R. Bard, Inc. (BCR) Receives Average Rating of "Hold" from Analysts www.americanbankingnews.com - November 27 at 12:34 PM |
 | Paul Tudor Jones: The Global Macro Trader finance.yahoo.com - November 25 at 3:37 PM |
 | Brokerages Expect C.R. Bard, Inc. (BCR) Will Post Quarterly Sales of $1.02 Billion www.americanbankingnews.com - November 25 at 9:44 AM |
 | C.R. Bard, Inc. (BCR) Expected to Announce Earnings of $3.12 Per Share www.americanbankingnews.com - November 23 at 3:10 AM |
 | CR Bard (BCR) a Strong Buy on Outstanding Quant Score - Investorplace.com investorplace.com - November 21 at 4:56 PM |
 | CR Bard (BCR) a Strong Buy on Outstanding Quant Score investorplace.com - November 21 at 12:06 PM |
 | BD Statement On Merit Medical Agreement To Purchase BD, Bard Product Lines finance.yahoo.com - November 16 at 11:54 AM |
C R Bard (NYSE:BCR) SEC Filings
This page is loading this company's SEC Filings. Please wait...
C R Bard (NYSE:BCR) Income Statement, Balance Sheet and Cash Flow Statement
C R Bard (NYSE BCR) Stock Chart for Sunday, April, 22, 2018
Loading chart…